Proteostasis landscapes of cystic fibrosis variants reveal drug response vulnerability
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2418407122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Eli Fritz McDonald und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Vanderbilt University, Nashville, TN 37240. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, Cystic Fibrosis, Proteostasis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, HHS | NIH | National Institute of General Medical Sciences.
Abstract (Originalsprache)
Cystic fibrosis (CF) is a lethal genetic disorder caused by variants in CF transmembrane conductance regulator (CFTR). Many variants are treatable with correctors, which enhance the folding and trafficking of CFTR. However, approximately 3% of persons with CF harbor poorly responsive variants. Here, we used affinity purification mass spectrometry proteomics to profile the protein homeostasis (proteostasis) changes of CFTR variants during correction to assess modulated interactions with protein folding and maturation pathways. Responsive variant interactions converged on similar proteostasis pathways during correction. In contrast, poorly responsive variants subtly diverged, revealing a partial restoration of protein quality control surveillance and partial correction. Computational structural modeling showed that corrector VX-445 failed to confer enough NBD1 stability to poor responders. NBD1 secondary stabilizing mutations rescued poorly responsive variants, revealing structural vulnerabilities in NBD1 required for treating poor responders. Our study provides a framework for discerning the underlying protein quality control and structural defects of CFTR variants not reached with existing drugs to expand therapeutics to all susceptible CFTR variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Vanderbilt University, Nashville, TN 37240.
- Center for Structural Biology, Vanderbilt University, Nashville, TN 37240.
- Chemical and Physical Biology Program, Vanderbilt University, Nashville, TN 37240.
- Department of Pharmacology, Vanderbilt University, Nashville, TN 37240.
- Institute for Drug Discovery, Leipzig University, Leipzig, SAC 04103, Germany.
- Department of Biological Sciences, Vanderbilt University, Nashville, TN 37240.
ORCID-Profile: Eli Fritz McDonald, Minsoo Kim, John A Olson, Jens Meiler, Lars Plate
Förderung
- NHLBI NIH HHS
- NIGMS NIH HHS
- HHS | NIH | National Institute of General Medical Sciences
- HHS | NIH | National Heart, Lung, and Blood Institute
Zitieren
APA
McDonald, E. F., Kim, M., Olson, J. A., Meiler, J., & Plate, L. (2025). Proteostasis landscapes of cystic fibrosis variants reveal drug response vulnerability. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2418407122
Vancouver
McDonald EF, Kim M, Olson JA, Meiler J, Plate L. Proteostasis landscapes of cystic fibrosis variants reveal drug response vulnerability. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2418407122
BibTeX
@article{McDonald2025,
author = {McDonald, Eli Fritz and Kim, Minsoo and Olson, John A and Meiler, Jens and Plate, Lars},
title = {Proteostasis landscapes of cystic fibrosis variants reveal drug response vulnerability},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2418407122}
}
EUVIMED